These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34659242)

  • 41. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.
    Kanakry JA; Kasamon YL; Bolaños-Meade J; Borrello IM; Brodsky RA; Fuchs EJ; Ghosh N; Gladstone DE; Gocke CD; Huff CA; Kanakry CG; Luznik L; Matsui W; Mogri HJ; Swinnen LJ; Symons HJ; Jones RJ; Ambinder RF
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1514-7. PubMed ID: 23871780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL; Atasoylu AA
    Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
    Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
    Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation.
    Luznik L; Engstrom LW; Iannone R; Fuchs EJ
    Biol Blood Marrow Transplant; 2002; 8(3):131-8. PubMed ID: 11939602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide].
    Sugita J
    Rinsho Ketsueki; 2020; 61(9):1402-1410. PubMed ID: 33162542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Induction of immune tolerance for allogenic recipient mice by non-myeloablative bone marrow transplantation].
    Chen BA; Bi YZ; Ding JH; Zhang Y; Gao C; Sun YY; Zhao G; Wang J; Cheng J; Sun XM; Schmitt M; Döhner H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1054-7. PubMed ID: 16403279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen.
    Dodd-O JM; Ganguly S; Vulic A; Panoskaltsis-Mortari A; McDyer JF; Luznik L
    Transplantation; 2016 Dec; 100(12):e140-e146. PubMed ID: 27861294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
    Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
    Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance.
    Iwai T; Tomita Y; Zhang QW; Shimizu I; Nomoto K; Yasui H
    Transpl Int; 2005 May; 17(12):795-803. PubMed ID: 15856178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone marrow chimerism and tolerance induced by single-dose cyclophosphamide.
    Okayama J; Ko S; Kanehiro H; Kanokogi H; Hisanaga M; Ohashi K; Sho M; Nagao M; Ikeda N; Kanamura T; Akashi S; Nakajima Y
    J Surg Res; 2004 Jul; 120(1):102-10. PubMed ID: 15172196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
    Kasamon YL; Luznik L; Leffell MS; Kowalski J; Tsai HL; Bolaños-Meade J; Morris LE; Crilley PA; O'Donnell PV; Rossiter N; Huff CA; Brodsky RA; Matsui WH; Swinnen LJ; Borrello I; Powell JD; Ambinder RF; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):482-9. PubMed ID: 19925877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
    Munchel AT; Kasamon YL; Fuchs EJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
    Williams L; Cirrone F; Cole K; Abdul-Hay M; Luznik L; Al-Homsi AS
    Front Immunol; 2020; 11():636. PubMed ID: 32373119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and limitations of cyclophosphamide-induced tolerance against alphaGal antigen.
    Shimizu I; Tomita Y; Iwai T; Kajiwara T; Okano S; Sueishi K; Nomoto K; Yasui H
    Scand J Immunol; 2005 Sep; 62(3):271-80. PubMed ID: 16179014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.
    Gorczynski RM; Chen Z; Zeng H; Gorczynski L; Terzioglu E
    Immunology; 1998 Feb; 93(2):221-9. PubMed ID: 9616372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation.
    Katsanis E; Stea B; Kovacs K; Truscott L; Husnain M; Khurana S; Roe DJ; Simpson RJ
    Transplant Cell Ther; 2022 Jul; 28(7):390.e1-390.e10. PubMed ID: 35460929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation.
    Fernandes JF; Bonfim C; Kerbauy FR; Rodrigues M; Esteves I; Silva NH; Azambuja AP; Mantovani LF; Kutner JM; Loth G; Kuwahara CC; Bueno C; Kondo AT; Ribeiro AAF; Kok F; Hamerschlak N
    Bone Marrow Transplant; 2018 Apr; 53(4):392-399. PubMed ID: 29330393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.